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Background: Vascular disease is promoted by systemic inflammation that can arise from sites distal to the affected
vessels. We sought to characterize the net inflammatory potential of serum from patients with coronary artery
disease (CAD) using cultured endothelial cells as a cumulative biosensor.
Methods and results: Serum samples from CAD patients (N = 45) and healthy control subjects (N = 48) were
incubated with primary human coronary artery endothelial cells at a 1:10 dilution for 4 h, followed by isolation of
the cellular RNA. Alteration of inflammation-responsive elements (adhesion molecules and cytokines) was assessed
by gene expression. Specific indicators included intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion
molecule-1 (VCAM-1), and interleukin-8 (IL-8). Additionally, the cytokine levels in serum samples from all subjects
were quantified. Serum from CAD subjects induced greater endothelial ICAM-1, VCAM-1, and IL-8 expression compared
to healthy control serum (p < 0.001 for each analysis). The three indicators of inflammatory potential (ICAM-1, VCAM-1,
and IL-8 mRNA) trended independently of each other and also of serum inflammatory biomarkers. IL-8 expression
correlated negatively with serum HDL levels but positively correlated with VLDL, plasminogen activator inhibitor-1 and
C-reactive protein. Interestingly, serum levels of cytokines in CAD patients were not statistically different from healthy
control subjects. A year of follow-up in a sub-group of CAD subjects revealed relatively stable measures.
Conclusions: As yet unidentified circulating factors in the serum of CAD patients appear to activate endothelial cells,
leading to upregulation of adhesion molecules and chemokines. This cumulative assay performed well in terms of
discriminating patients with CAD compared to healthy subjects, with greater range and specificity than specific
inflammatory markers.
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Vascular disease is an inflammatory condition wherein
activated endothelial cells mediate the recruitment of
immune cells into damaged areas of the vessel wall, pro-
moting oxidative injury, pathological lesion growth and
increased histological complexity [1]. Systemic inflam-
mation arising at distal sites, such as the lungs or liver,* Correspondence: mcampen@unm.edu
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unless otherwise stated.may also contribute to the inflamed state of coronary or
cerebral vessels through unknown mechanisms [2-6].
Circulating factors likely have a causal role in promoting
endothelial cell activation, a state characterized by pres-
entation of adhesion molecules and release of chemo-
kines [7,8]. Specific circulating acute phase proteins such
as C-Reactive Protein (CRP) and tumor necrosis factor-α
(TNFα) are both associated with vascular disease and
can independently activate endothelial cells via NF-κB
pathways [9-11]. However, because the blood contains
thousands of factors, the discrete assessment of specifichis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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influence that the blood conveys to the endothelial wall.
Not surprisingly, such individual factors contribute only
modestly to cardiovascular risk prediction or reclassifica-
tion beyond conventional Framingham risk factors [12]
and we propose that this gap between biomarkers and
outcome is blurred by the complex composition of the
blood and numerous unaccounted factors.
We have developed a novel, less biased approach to
assess what we believe to be a functional index of the
total inflammatory potential of the serum [13]. By asses-
sing canonical inflammatory response patterns in primary
human coronary artery endothelial cells (hCAECs) treated
with dilute samples of serum or plasma, the endothelial
cells act as biosensors of the complete serum milieu. This
assay was initially developed to explore the relatively mod-
est impact of inhaled pollutants on cardiovascular health.
It was found that serum from healthy individuals, when
obtained shortly following controlled exposures to diesel
engine emissions or nitrogen dioxide, carried a greater
potential for inducing endothelial cell adhesion mole-
cules and chemokines compared to sham exposure [13].
Similarly, whole serum has been used to identify a net
inflammatory influence of cigarette smoking, leading to
reductions of eNOS expression and increased reactive
oxygen species [14,15]. Conversely, in a larger cohort of
healthy subjects taking a month-long regimen of a
resveratrol-containing nutraceutical, we found that circu-
lating inflammatory potential decreased relative to pre-
treatment plasma, while placebo administration caused no
clear trend and no changes in other biometrics were ob-
served [16]. The overall approach has also proven useful
in animal toxicology research [17,18], but the linkage to
clinically-relevant disease has yet to be assessed.
Thus, the value of this assay paradigm remains uncer-
tain with respect to clinical outcomes. Many questions
remain unanswered, such as whether elevations in net
serum inflammatory potential contribute to chronic car-
diovascular disease and whether such measures have pre-
dictive or diagnostic value. The present study conducted a
side-by-side comparison of stabilized coronary artery dis-
ease patients on standard-of-care medication with a separ-
ate cohort of healthy subjects.
Methods
Patient population
Patients with CAD were recruited while hospitalized at
the University of New Mexico Hospital for an acute cor-
onary syndrome event (unstable angina, non-ST eleva-
tion myocardial infarction, or ST-elevation myocardial
infarction) to participate in a health outcomes study de-
signed to assess the benefit of an interdisciplinary car-
diovascular risk reduction clinic (CRRC), as compared to
usual care. The study was approved by the University ofNew Mexico Health Sciences Center Human Research
Review Committee and all study patients provided in-
formed consent.
As part of the study, blood samples were collected
from all patients for assessment of a variety of traditional
and non-traditional risk factors (lipids, HbA1c, homo-
cysteine, malondialdehyde [MDA], plasminogen activa-
tor inhibitor-1) and a portion of the samples were
stored for future use. Patients randomized to the CRRC
were evaluated by both a cardiologist and a clinical
pharmacist, who devised an appropriate treatment plan
based upon identified cardiovascular disease risk fac-
tors. Patients randomized to usual care received follow-
up at the discretion of their primary care providers and/
or specialist providers.
The majority of CAD patients were on standard-of-care
pharmacotherapy, including strategies to reduce choles-
terol, glucose, blood pressure, platelet aggregation, and
tobacco cessation where appropriate. The serum samples
used in this analysis were collected at the initial outpatient
follow-up study visit to the CRRC.
Healthy control subjects were recruited through the
University of New Mexico Clinical and Translational
Science Center for routine health screens. Subjects were
recruited by newspaper or radio advertisements from
the community. Exclusion criteria included - 1) history
of diabetes mellitus, atherosclerotic cardiovascular dis-
ease, chronic kidney disease, or anorexia nervosa; 2) use
of statin class of drugs; 3) current smoking or having
quit smoking within previous two months; 4) pregnancy
and nursing state; 5) presence of lung diseases other
than asthma; 6) stroke in prior 3 months; 7) aortic
aneurysm; and 8) failure to expectorate adequate-quality
sputum in response to induction. In addition, all tests were
delayed in the event of an acute infection or surgery within
the prior 4 weeks and respiratory tract infections or asthma
exacerbations within the prior 8 weeks to minimize the ef-
fect of these factors on measurements. For actively men-
struating women, the testing was done within 3–14 days
following the cessation of menstrual flow (a period of
high estrogen and low progesterone) to standardize the
effect of sex hormones.Bioelectrical impedance
CAD participants were assessed for body composition in
a fasting state using a Quantum II Bioelectrical Imped-
ance Analyzer (RJL Systems, Clinton Township, MI)
using the method described by Heyward [19]. Results
for bioelectric impedance were analyzed with Compre-
hensive Body Composition Software (Human Kinetics,
1997, Champaign, Ill) and percent body fat mass was
calculated using standard reference equations appropri-
ate for race and gender [19].
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The endothelial cell biosensor assay (Figure 1) was con-
ducted as previously described [13,16]. Briefly, hCAECs
(Lonza, Allendale, NJ) were seeded in a 24-well plate and
grown to confluence in complete media (Lonza). The cells
were then serum-starved with Basal Media (Lonza) for
24 hours prior to exposure. Confluent hCAEC were incu-
bated with 10% serum obtained from coronary artery dis-
ease (CAD) patients (ie., 50 μl serum in 450 μl media, per
well) or 10% serum obtained from otherwise healthy indi-
viduals. Each plate of cells was treated with approximately
equal numbers of subjects from each group in a random-
ized, blinded fashion. The samples were incubated for
4 hours at 37°C. RNA was extracted from the cells and
cDNA was made using a ThermoCycler (Model # PTC-
200; MJ Research). The cDNA was used to determine
gene expression via quantitative polymerase chain reac-
tion (LightCycler 480 II, Roche, Indianapolis, IN). Spe-
cific targets included interleukin-8 (IL-8), intercellular
adhesion molecule-1 (ICAM-1), and vascular cell adhe-
sion molecule-1 (VCAM-1), with TATA-box protein
used as a housekeeping gene.
Serum cytokine measurements
Serum samples from healthy and CAD patients were ana-
lyzed using an electrochemiluminescence detection system
(Meso Scale Discovery, Rockville, MD). The serum samples
were analyzed for the presence of CRP, soluble ICAM-1,
soluble VCAM-1, serum amyloid A (SAA), TNF-α, IL-6,
IL-8, and IL-1β using commercially-available kits.
Data analysis
Gene expression data were log10-transformed for nor-
mality. Data were analyzed between groups (CAD versus
control) via Satterthwaite’s t-test (SAS v9.4). A multivari-
ate analysis confirmed this difference between CAD and
control outcomes after adjusting for age, sex, and BMI.
Correlational (Spearman) and multivariate analysis wasFigure 1 Endothelial cell biosensor approach. Primary coronary artery e
for 4 h, followed by isolation of RNA, and then assayed for transcriptional rcarried out on the CAD patient outcomes relative to
demographic and clinical data (SAS).
Results
Cohort data
A total of 48 patients with CAD and 45 healthy control
subjects were included in the study. Subjects were self-
selected and inclusion criteria allowed for a wide range
of CAD etiology and manifestations. Table 1 summarizes
the demographic information. The CAD patients in this
unmatched study were expectedly older than control
subjects and had a disproportionate prevalence of CV
risk factors, including diabetes, body mass index (BMI),
hypertension, hypercholesterolemia and current tobacco
use. Importantly, a sufficiently overlapping range of demo-
graphic factors permitted multivariate assessment to elim-
inate all potential major effect modifiers, in terms of
endothelial cell responses to serum, described below. The
CAD cohort was comprised of patients with single and
multiple vessel disease, and were recorded on admission
as being a mix of non-ST segment elevation myocardial
infarction (NSTEMI) and ST segment elevation myocar-
dial infarction (STEMI), as well as unstable angina. Table 2
provides all additional personal health data from the CAD
patient population that were available.
Serum from CAD patients has greater inflammatory
potential than serum from healthy subjects
hCAECs treated with 10% serum from CAD subjects
showed substantial increases in IL-8, ICAM-1, and
VCAM-1 expression, compared to hCAECs treated with
serum from healthy control subjects (Figure 2). Endo-
thelial mRNA expression of IL-8 and VCAM-1 were ap-
proximately 80% higher in hCAECs treated with CAD
patient serum compared to controls (p < 0.0001). ICAM-1
expression was more stable at approximately 30% above
control (P = 0.0009) and with less overall variability. The
distribution patterns of gene expression for each of thesendothelial cells are incubated with 10% serum from individual patients
esponses.







Age (Mean ± SE; range) 31.7 ± 13.5; 18-61 56.5 ± 7.9; 36-77
Gender (% female) 71% 41.7%
BMI (Mean ± SE; range) 22.3 ± 1.7; 18.7-25.5 29.9 ± 6.4; 17.2-48.2
Fat composition
(Bioelectric impedence)




4.7% Asian 36.8% White







Extent of CAD (single,
multi vessel), N (%)




NA 14 (29%), 21 (44%),
13 (27%)
Table 2 Further clinical data from CAD cohort
Mean SD Min Max
Total cholesterol (mg/dl) 149.9 39.4 76 241
LDL 88.6 31.7 34 175
HDL 40.2 12.1 25 88
HDL2 9.3 4.9 4 32
HDL3 30.9 7.9 18 56
VLDL 22.0 8.3 12 64
VLDL 1,2 9.8 3.2 5.6 20
VLDL 3 18.1 46.2 7 341
Triglycerides 156.1 74.8 5 323
Lp(a) 6.8 3.9 3 17
IDL 8.4 5.5 1 24
Glucose (mg/dL) 115.8 37.5 81 265
HbA1c(%) 7.63 1.88 5.4 11.4
Homocysteine 9.25 4.00 4.6 24.6
Insulin (uIU/mL) 14.09 8.02 2.4 43.5
Fibrinogen (mg/dL) 363.2 89.8 231 660
PAI (IU/ml) 15.1 13.1 0.1 50
UrMicAlb (mgALB/gCrea) 77.1 271.6 0.6 1481.6
SBP 130 19 100 186
DBP 74 11 48 100
HR 67 11 43 89
Weight(kg) 85.5 17.4 53.4 123.25
Bioelectric impedence 36.1 9.08 22.6 48.8
MDA 0.236 0.089 0.094 0.414
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the marker expression from individuals varied consider-
ably. Cross-correlations ranged from moderate (R = 0.534
for VCAM-1 and ICAM-1) to low (R = 0.201 for ICAM-1
and IL-8), implying that these responses might be influ-
enced by different factors – or cumulative factors - in
the serum.Glucose control 25%
ACE inhibitors or ARBs 75%
β-blockers 68.8%Relationship of endothelial responses to serum to time
post-event and longitudinal trends
As many serum components can be acutely altered as a
result of major cardiac events, or may trend with age
and/or time, we examined the impact of temporality on
serum-treated hCAEC mRNA expression in both the
cross-sectional samples, as well as with a sub-cohort of
longitudinally followed CAD subjects. All samples were
obtained from patients with known CAD, either from
having previously suffered an acute myocardial infarc-
tion or angina attack. The average time post-event was
slightly greater than one year (400 days), but 5 subjects
enrolled in the study within 2 months of the precipitat-
ing event and 6 subjects were greater than 2 years past
their event. The earliest enrolled subject had an event
16 days prior to the initial visit. In general, this cross-
sectional data set did not reveal strong trends of temporalresolution of the bioactivity of the serum (Figure 3A-C).
For serum-treated hCAEC IL-8 expression, there were
no significant trends. hCAEC mRNA for ICAM-1 and
VCAM-1 demonstrated modest reductions relative to
the time post-event (P = 0.033 and 0.055, R2 = 0.10 and
0.08, respectively). As serum samples more proximal to
the event than 16 days were not available, it is not
known if the serum obtained within hours or days after
the event might be more inflammatory. However, from
months-to-years after an event, the data suggest consid-
erable stability.
In a limited cohort of subjects (N = 11), four longitudin-
ally obtained serum samples were available for approxi-
mately one year after the initial clinic visit (Figure 3D-F).
Figure 2 Endothelial cell expression of IL-8, ICAM-1, and VCAM-1 mRNA in response to incubation with 10% serum from healthy
controls or CAD cohort. Significance was assessed with a Student’s t-test. The differences between groups remained significant after controlling
for age, sex, and body mass index, and all potential interactions using a multivariate analysis of variance (general linear model).
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trends, in terms of activation of hCAEC responses, in
these subjects and found that no absolute trends were
observed over the year of follow-up. However, clear vari-
ability in endothelial cell responses to serum obtained at
different visits was evident. As the medical records for
these subjects lacked temporal details in terms of symp-
toms and medications, we are unable to ascribe such
short-term trends to any clear change in health status. Im-
portantly, the lack of long term trends in this sub-cohort
of CAD subjects on standard of care medication is con-
sistent with the fact that all of these subjects survived be-
yond this year of follow-up.
CAD Manifestation effects on serum inflammatory
potential
Medical records allowed for initial event categorization
of CAD subjects. We therefore considered an intra-cohort
comparison for subjects whose initial presentation was a
myocardial infarction (with or without ST elevation) or
unstable angina (Figure 4). A slight trend for increased
expression of the gene transcripts was noted for pa-
tients admitting with an MI, which was only significant
for VCAM-1 (P = 0.0266). No significant differences
were observed between subjects admitting with ST-
elevation MI or non-ST elevation MI (data not shown).These findings are consistent with the hypothesis that
greater inflammatory potential in the serum may lead
to more severe vascular pathology, although the results
are associative.
Endothelial cell responses to serum were not impacted by
sex, age or BMI
Importantly, the significant differences in endothelial ex-
pression of IL-8, ICAM-1, and VCAM-1 in response to
patient serum remained significant even after adjusting
for the potential major effect modifiers of sex, age, and
BMI that were clearly different between cohorts. Direct
comparisons across sex, age, and BMI are shown in
Figure 5. For each mRNA target, it is clear that CAD
subjects were elevated compared to healthy controls,
but there was not impact of sex on the endothelial cell
responses to serum in either healthy or CAD cohorts
(Figure 5A-C). Similarly, age and BMI showed no clear
trends across the complete range of either variable
(Figure 5D-I).
Multivariate regression was also applied to test the tran-
scriptional outcomes relative to the potential effect modi-
fiers. In considering all variables and potential interactions
among sex, age, and BMI as confounders, differences
between healthy and CAD subjects for expression of IL-
8, ICAM-1, and VCAM-1 remained significant. Thus,
Figure 3 Temporal trends on serum inflammatory potential. Cross-sectional samples were obtained from 16d to several years after initial
cardiac events (A-C). The time post-event had minimal effect on IL8 mRNA expression, but factors in the serum that drove ICAM-1 and VCAM-1
expression may have been higher acutely following the event. Longitudinal serum samples obtained approximately every 3 months from a
limited cohort of CAD subjects were assessed for inflammatory potential independently from healthy subjects (D-F).
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that the CAD condition alone imparts an independent
pro-inflammatory effect on the serum.Demographic factors that correlate with hCAEC responses
In exploring potential factors that may contribute to
serum-induced endothelial cell responses, we found a
number of demographic factors in CAD patients that
correlated with IL-8, ICAM-1 and VCAM-1 expression
(Table 3). IL-8 expression associated with a number of
factors, positively trending with serum levels of VLDL1/2,
CRP, and PAI-1, while negatively trending with serum
glucose and HDL levels. VCAM-1 expression correlated
with both smoking and serum homocysteine levels, while
ICAM-1 expression correlated with age, serum homo-
cysteine, and MDA. While serum homocysteine trended
negatively with inflammatory potential, it should be
noted that out of 51 patients, only 3 values for homo-
cysteine were out of normal range, and only two of these
were paired with a measure for VCAM-1 mRNA. Fewerdemographic and personal health data were available for
our control population, and those few factors analyzed
(age, BMI, gender) did not correlate with endothelial
cell responses to serum.
As IL-8 expression had the most robust correlates, we
developed a regression model to better understand the
factors that predict this outcome (Table 4). This model
confirmed the outcomes in the correlational analysis,
providing confidence for the roles of serum VLDL, CRP,
and glucose levels in driving the IL-8 related inflamma-
tory potential. However, these variables only explained a
small portion of the inflammatory potential, indicating
that other unmeasured factors are also mediators.Cytokine Levels did not explain the difference in serum
inflammatory potential between groups
To assess whether inflammatory cytokines might ex-
plain differences in the serum inflammatory potential
between healthy and CAD subjects, we measured 8 key
inflammatory cytokines in serum from all patients using
Figure 4 Serum from subjects with diagnosed myocardial
infarction (MI) induced greater VCAM-1 induction compared
to serum from subjects with unstable angina (P = 0.027 by
one-tailed t-test on natural-log-transformed data). Both IL-8 and
ICAM-1 trends were non-significant.
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statistically significant differences were noted for IL-1β,
IL-6, IL-8, TNFα, C-Reactive Protein, soluble VCAM-1,
or Serum Amyloid A, either in terms of mean or distribu-
tion, between healthy and CAD cohorts. A modest, but
non-significant increase in soluble ICAM-1 was noted
however (49.1 ± 8.1 controls versus 84.1 ± 14.4 in CAD pa-
tients, P = 0.086).Discussion
The present study assessed cumulative serum inflamma-
tory potential from a cohort of CAD patients in stable
condition under standard-of-care for medications and life-
style adjustments, using an endothelial biosensor assay.
Utilization of circulating biomarkers has proven valuable
for diagnostic and prognostic purposes in atherosclerotic
disease, but even the most predictive single mediators
provide only small incremental improvements in overall
prediction of risk or patient reclassification [20,21].Endothelial inflammatory response to serum from CAD
patients was significantly increased compared to re-
sponses to control subject serum, despite observing that
most measured circulating cytokines were no different
between these cohorts. Additionally, our characterization
of the temporal dynamics of this assay reveals stability
over the course of a year of follow-up, albeit with some la-
bility, reflecting a generally successful course of treatment.
The value of this assay paradigm - using endothelial cells
as “biosensors” of circulating inflammatory potential -
remains incompletely appreciated but highly promising,
as the ability to discriminate clinical populations in a
manner consistent with a diagnosed clinical condition
would be a clear advantage over assessment of single or
even multiple biomarkers that can not discriminate
from healthy subjects.
Serum obtained from patients with a previous history
of a major coronary vascular event showed a greater
potential for inducing endothelial cell inflammatory re-
sponses, such as IL-8, VCAM-1, and ICAM-1 expres-
sion, compared to serum from healthy individuals. The
CAD patients, all substantially post-event (mean = 1.1y;
range = 16d − 7.5y), were expectedly receiving numerous
medications (>7) as standard-of-care. CAD subjects were
generally prescribed at least one lipid control agent (e.g.,
statin), an antiplatelet agent (e.g., aspirin and/or clopido-
grel), and patients with Type 2 Diabetes Mellitus were
also taking at least one glucose control agent (Table 2).
Many of these medications have reported pleiotropic
anti-inflammatory effects, which may explain the reduc-
tion of cytokine levels to control cohort values. In recent
reports, statins have been shown to reduce CRP levels.
For instance 6 months of 10 mg/day of Atorvastatin led
to a 26% drop in CRP and also diminished the predictive
value of CRP, in terms of risk for major adverse cardio-
vascular events [22]. Simvastatin therapy provides simi-
lar results, while combined simvastatin and ezetimibe
led to a >35% reduction on CRP [23]. Other standard of
care medications likely contribute further to this CRP
lowering effect, including aspirin [24], clopidogrel [25],
and glucose control medications such as rosiglitazone
[26]. Other inflammatory cytokines, including IL-6 and
TNF-α, appear to be similarly affected by statins and
antiplatelet medications [27,28]. Thus, the ability to differ-
entiate healthy control subjects and patients with diag-
nosed CAD using such cytokine markers is substantially
hampered once such medications are implemented [22].
Importantly, serum inflammatory potential determined
with the novel endothelial bioassay remained elevated
compared to healthy control subjects, despite the medica-
tion use, although the prognostic/diagnostic value of such
outcomes remains to be defined.
In previous research, we have found this endothelial bio-
assay paradigm valuable for assessing potential benefits of
Figure 5 Potential effect modifiers sex, Age, and BMI have no clear influence on serum inflammatory potential. Sex related differences
are negligible in determining the differences between healthy and CAD serum-induced endothelial cell responses (A-C). Similarly, Age does not
appear to drive any trends for serum-induced IL-8, ICAM-1, or VCAM-1 mRNA expression (D-F). While BMI is limited in the control population, the
lack of consistent trends in controls and CAD across various BMI ranges reduces confidence that this factor has a clear role in drive the serum
inflammatory potential (G-I).
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adult population [16]. Whereas serum markers of inflam-
mation, such as interferon-gamma and interleukin-1β, did
not change with resveratrol/grape seed extract treatment,
compared to placebo, endothelial cells incubated with
serum obtained after the month-long resveratrol/grape
seed extract regimen exhibited consistently lower expres-
sion of IL-8, ICAM-1, and VCAM-1 mRNA compared to
baseline responses. Conversely, in studies of air pollution
health effects in another healthy cohort, we observed anincrease in the serum inflammatory potential following in-
halation of diesel exhaust emissions and nitrogen dioxide
[13]. The degree of inflammatory potential change was
smaller than that seen with the differences in the present
study, on the order of 20-30% increases, acutely, com-
pared to 30-90% increases for mRNA responses to serum
between CAD patients and a healthy cohort. These out-
comes are consistent with earlier research using this
general approach. Barbieri and colleagues found that
serum from cigarette smokers could induce COX-2 and
Table 3 Factors in CAD patients that correlate with








C-Reactive protein 0.329 0.038







Time post-event −0.312 0.033
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peared dependent on TNFα and interleukin-1β [15]. Simi-
larly, Barua and colleagues treated hCAECs with serum
from smokers and found a down-regulation of eNOS pro-
tein activity that was reversible by the addition of super-
oxide dismutase and catalase [14]. The present study of
CAD provides a vital clinical anchor for understanding
these earlier studies that used this serum inflammatory
potential assay, showing that elevated endothelial cell
responses to serum is consistent with diagnosed vascu-
lar disease.
Several study limitations are also viewed as opportun-
ities for future research, as the overall concept of holistic
cell-based responses to whole serum remains quite novel
and unexplored. For one, while IL-8, VCAM-1, and
ICAM-1 mRNA are consistently reported as involved in
vascular disease progression, both in clinical studies and
basic research, there are a number of important response
factors that have not been assessed. It is highly probable
that many other transcripts are more responsive to the in-
flammatory factors in the CAD serum, or that specific
proteins may be produced, expressed on the cell surface,Table 4 Predictive variables for IL8 response using a linear re
Variable Parameter estimate Std error
Intercept 0.141 0.0815
VLDL 1/2 0.0199 0.0062
CRP 0.0100 0.0028
Glucose −0.0012 0.0005or secreted in a selective manner. It is likely that endothe-
lial genomic or proteomic outcome patterns would iden-
tify stronger response elements or provide “fingerprint”
responses to specific clinical conditions or allow differenti-
ation between acute environmental influences (i.e., diet,
air pollution) and chronic syndromes (i.e., type 2 diabetes
mellitus or end stage renal disease).
Secondly, we have yet to clearly link endothelial cell
responses to serum with outcomes of morbidity and/or
mortality, thus the clinical value of the present study re-
mains uncertain. Our previous work suggests that this
approach may be valuable for studies of toxicology [13]
or therapeutic efficacy [16], and the present study high-
lights a potential for diagnostic purposes. However, we
did not have sufficient subject numbers to conduct a
complete follow-up study to determine whether the
serum inflammatory potential may help in the predic-
tion of adverse outcomes.
Lastly, there is inherently concern relative to the un-
matched study cohorts, despite our findings revealing
negligible influence of sex, age, or BMI on the coronary
artery endothelial cell transcriptional responses to CAD
patient serum. Improved matching in future research
will certainly provide greater confidence in this outcome.
However, our findings remain notable due to the power
of this novel approach to discriminate these populations
when conventional inflammatory cytokines did not.
There is a vast amount of clinical and research efforts
invested in the use of circulating biomarkers. The find-
ing in the present study that CAD patients on standard-
of-care medication showed no difference in cytokine
profiles from a cohort that was younger, had a lower
BMI, and more predominantly female, is naturally a
concern and clear motivation for the development of
novel diagnostic and prognostic markers, such as pur-
sued in the present study.
Conclusions
The use of cells as biosensors to detect cumulative circu-
lating inflammatory may have significant clinical value.
Serum contains thousands of factors - proteins, lipids, and
metabolites - that can be augmented by numerous path-
ologies. Hundreds of potential drivers of endothelial cell
activation and vascular inflammatory pathologies exist,
such as myeloperoxidase, oxidized lipids or lipoproteins,gression model





Figure 6 Cytokine and acute phase proteins measured by electrochemiluminescence in serum from healthy controls and CAD cohort.
Significance was assessed with a Student’s t-test.
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molecular patterns (DAMPs). Additionally, endogenous
proteins may be modified (fragmented or adducted) by
reactive molecules, leading to altered biological activity
or pathological epitopes. The present findings, com-
bined with previous experience with this assay, highlight
the potential usefulness of a cumulative bioactivity
response, compared to measurements of individual fac-
tors to assess an overall inflammatory potential of thecirculation. Sophisticated proteomic, lipidomic and meta-
bolomics approaches will naturally be valuable to establish
key drivers and link back to clinical course. However, we
remain skeptical that any single marker will explain the
net inflammatory serum potential; thus, there is need for
holistic assessments such as this endothelial biosensor
method. Future work is required to address the value of
this approach for prediction of risk, efficacy of therapies,
or safety of pharmaceuticals.
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